These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10889599)

  • 1. Interleukin 2 treatment for HIV infection.
    Blankson J; Siliciano RF
    JAMA; 2000 Jul; 284(2):236-8. PubMed ID: 10889599
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapy of HIV infection: combination drug therapy effective, immunotherapy still experimental].
    Dtsch Med Wochenschr; 1997 Apr; 122(15):A32. PubMed ID: 9147936
    [No Abstract]   [Full Text] [Related]  

  • 3. Interleukin-2 in combination with zidovudine and didanosine is able to maintain high levels of CD4 cells and undetectable HIV viraemia.
    Simonelli C; Zanussi S; Comar M; Vaccher E; Giacca M; De Paoli P; Tirelli U
    AIDS; 1998 Jan; 12(1):112-3. PubMed ID: 9456263
    [No Abstract]   [Full Text] [Related]  

  • 4. IL-2 plus HAART reduces HIV in immune system "hiding places".
    WORLD; 1998 Dec; (No 92):7. PubMed ID: 11365976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-2: trials and tribulations.
    Kuritzkes DR
    J Infect Dis; 2009 Jul; 200(2):164-5. PubMed ID: 19508158
    [No Abstract]   [Full Text] [Related]  

  • 6. Interleukin-2 clinical trials.
    Newsline People AIDS Coalit N Y; 1998 Sep; ():58. PubMed ID: 11367495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved treatment results with interleukin-2.
    HIV Hotline; 1998 May; 8(2):13-4. PubMed ID: 11365363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher HIV-1 DNA associated with lower gains in CD4 cell count among patients with advanced therapeutic failure receiving optimized treatment (ANRS 123--ETOILE).
    Avettand-Fenoel V; Bouteloup V; Mélard A; Fagard C; Chaix ML; Leclercq P; Chêne G; Viard JP; Rouzioux C;
    J Antimicrob Chemother; 2010 Oct; 65(10):2212-4. PubMed ID: 20667886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-2 therapy and CD4+ T cells in HIV-1 infection.
    Vento S; Cainelli F; Temesgen Z
    Lancet; 2006 Jan; 367(9505):93-5. PubMed ID: 16413860
    [No Abstract]   [Full Text] [Related]  

  • 10. Nadir CD4+ T cell count predicts response to subcutaneous recombinant interleukin-2.
    Markowitz N; Bebchuk JD; Abrams DI;
    Clin Infect Dis; 2003 Oct; 37(8):e115-20. PubMed ID: 14523786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug combination treats brain cancer.
    AIDS Patient Care STDS; 1999 Dec; 13(12):755. PubMed ID: 10743546
    [No Abstract]   [Full Text] [Related]  

  • 12. Aldesleukin therapy in HIV-infected patients.
    Sundin DJ; Wolin MJ
    Am J Health Syst Pharm; 1998 Jul; 55(14):1520-3. PubMed ID: 9676300
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial.
    Davey RT; Murphy RL; Graziano FM; Boswell SL; Pavia AT; Cancio M; Nadler JP; Chaitt DG; Dewar RL; Sahner DK; Duliege AM; Capra WB; Leong WP; Giedlin MA; Lane HC; Kahn JO
    JAMA; 2000 Jul; 284(2):183-9. PubMed ID: 10889591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Definitive results: IL-2 does not benefit HIV-infected patients. Interleukin-2 improves CD4-cell recovery in patients on antiretroviral therapy, but that benefit does not translate into lower risks for disease or death.
    Hicks CB
    J Watch AIDS Clin Care; 2010 Jan; 22(1):4. PubMed ID: 20617576
    [No Abstract]   [Full Text] [Related]  

  • 15. IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy--results from the ANRS CO4 cohort.
    Fontas E; Kousignian I; Pradier C; Poizot-Martin I; Durier C; Weiss L; Levy Y; Costagliola D; ;
    J Antimicrob Chemother; 2010 Oct; 65(10):2215-23. PubMed ID: 20702463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus.
    Kovacs JA; Vogel S; Albert JM; Falloon J; Davey RT; Walker RE; Polis MA; Spooner K; Metcalf JA; Baseler M; Fyfe G; Lane HC
    N Engl J Med; 1996 Oct; 335(18):1350-6. PubMed ID: 8857018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin 2 and HIV RNA Levels.
    Go R; Steigbigel R
    Arch Intern Med; 2007 Oct; 167(19):2144-5; author reply 2145. PubMed ID: 17954814
    [No Abstract]   [Full Text] [Related]  

  • 18. SILCAAT and ESPRIT: taking stock.
    Gazzard B
    J HIV Ther; 2010 Mar; 15(1):1. PubMed ID: 21180230
    [No Abstract]   [Full Text] [Related]  

  • 19. Report from the 16th Conference on Retroviruses and Opportunistic Infections. No clinical benefit from adding IL-2 to ART.
    Henry K
    J Watch AIDS Clin Care; 2009 Apr; 21(4):29-30. PubMed ID: 19544613
    [No Abstract]   [Full Text] [Related]  

  • 20. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.
    Lafeuillade A; Hittinger G; Chadapaud S; Maillefet S; Rieu A; Poggi C
    HIV Clin Trials; 2002; 3(4):263-71. PubMed ID: 12187499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.